Drug Trial Radar · NCT07015983
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
89
Planned (sponsor's estimate)
Start
Jul 14, 2025
Primary completion
May 17, 2028
Study completion Jun 15, 2032
Sponsor
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jun 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety and drug levels of CC-97540 in participants with active systemic lupus erythematosus (SLE) including lupus nephritis with inadequate response to glucocorticoids and at least 2 immunosuppressants.
Conditions
- Lupus Erythematosus, Systemic
- Lupus Nephritis
Interventions
CC-97540Drug
Specified dose on specified days
FludarabineDrug
Specified dose on specified days
CyclophosphamideDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants achieving drug-free Definition of Remission in Systemic Lupus Erythematosus (DORIS) remissionTime frame: At month 6
Locations
97 sites in 16 countries. Site status is shown where the registry gives one.
Local Institution - 0106
Phoenix, Arizona
Local Institution - 0038
Los Angeles, California
Local Institution - 0051
Los Angeles, California
Local Institution - 0093
Newport Beach, California
Lucile Packard Children's Hospital
Palo Alto, California
University of Colorado Anschutz Medical Campus
Aurora, Colorado
Colorado Blood Cancer Institute
Denver, Colorado
Mayo Clinic in Florida
Jacksonville, Florida
University of Miami Hospital and Clinics, Sylvester Cancer Center
Miami, Florida
Local Institution - 0073
Orlando, Florida
Moffitt Cancer Center
Tampa, Florida
USF Health
Tampa, Florida
Florida Medical Clinic Orlando Health
Zephyrhills, Florida
Emory University School of Medicine
Atlanta, Georgia
Local Institution - 0079
Atlanta, Georgia
Northside Hospital
Atlanta, Georgia
Local Institution - 0108
Indianapolis, Indiana
Local Institution - 0086
Baton Rouge, Louisiana
Local Institution - 0110
Shreveport, Louisiana
Local Institution - 0094
Boston, Massachusetts
Local Institution - 0096
Ann Arbor, Michigan
Local Institution - 0011
Rochester, Minnesota
Atlantic Health System Overlook Medical Center
Summit, New Jersey
Local Institution - 0101
Manhasset, New York
Local Institution - 0082
New York, New York
Hospital for Special Surgery
New York, New York
Icahn School of Medicine at Mount Sinai
New York, New York
Columbia University Irving Medical Center
New York, New York
Columbia University Pediatrics
New York, New York
Weill Cornell Medical College
New York, New York
Local Institution - 0111
Stony Brook, New York
Carolinas HealthCare System SouthPark
Charlotte, North Carolina
Local Institution - 0135
Winston-Salem, North Carolina
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
Local Institution - 0083
Philadelphia, Pennsylvania
Baptist Memorial Hospital
Memphis, Tennessee
Baylor Scott and White Research Institute
Dallas, Texas
Local Institution - 0098
Dallas, Texas
Local Institution - 0104
San Antonio, Texas
Showing 40 of 97 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.